Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.
Lillian M GuentherR Grant RowePatricia T AcharyaDavid W SwensonStephanie C MeyerCatherine M ClintonDongjing GuoMadhumitha SridharanWendy B LondonHolcombe E GrierKirsten EcklundKatherine A JanewayPublished in: Pediatric blood & cancer (2017)
PD by RECIST predicts poor outcome in localized disease patients. In bone lesions, chemotherapy proven to improve overall survival does not result in radiographic responses as measured by RECIST. Further investigation of RECIST in pulmonary metastatic disease in osteosarcoma is needed.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- small cell lung cancer
- prognostic factors
- pulmonary hypertension
- sentinel lymph node
- rectal cancer
- bone mineral density
- radiation therapy
- patient reported outcomes
- soft tissue
- bone regeneration
- free survival